No discrete molecular target – cell replacement therapy

The term No discrete molecular target – cell replacement therapy refers to a therapeutic modality rather than a specific molecular entity like a protein or enzyme. This classification is used in pharmacological databases, such as ChEMBL, to describe interventions where the primary mechanism of action is the introduction of whole, functional cells into a patient to restore biological function (ChEMBL, 2024). Unlike traditional small molecules or biologics that target specific receptors, cell replacement therapy utilizes the complex, multi-faceted biological activities of live cells to treat diseases such as Type 1 diabetes through islet cell transplantation or hematological cancers via stem cell grafts (NIH, 2023). These therapies aim for long-term integration and physiological regulation within the host environment, often providing functions that cannot be replicated by single-target drugs (PubMed, 2022). Because these treatments involve living biological units, they present unique clinical challenges, including the risk of immune rejection, the potential for unintended cellular differentiation, and the need for complex manufacturing and delivery protocols (StatPearls, 2023). This category highlights a shift in regenerative medicine toward holistic cellular restoration rather than isolated molecular modulation.

Other names

Cell replacement therapyCell-based therapyRegenerative medicineCytotherapyStem cell therapyCellular transplantation

Restoration of physiological function through the transplantation of functional, viable cells to replace dead, damaged, or dysfunctional endogenous cell populations.